Literature DB >> 32493185

A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation.

Livia A Goldraich1, Santiago A Tobar Leitão2, Fernando L Scolari2, Fabiana G Marcondes-Braga3, Marcely G Bonatto4, Dipika Munyal5, Jennifer Harrison5, Rafaela V P Ribeiro6, Estela Azeka3, Diogo Piardi7, Maria R Costanzo8, Nadine Clausell7.   

Abstract

Heart transplantation is the standard of therapy for patients with end-stage heart disease. Since the first human-to-human heart transplantation, performed in 1967, advances in organ donation, surgical techniques, organ preservation, perioperative care, immunologic risk assessment, immunosuppression agents, monitoring of graft function and surveillance of long-term complications have drastically increased recipient survival. However, there are yet many challenges in the modern era of heart transplantation in which immunosuppression may play a key role in further advances in the field. A fine-tuning of immune modulation to prevent graft rejection while avoiding side effects from over immunosuppression has been the vital goal of basic and clinical research. Individualization of drug choices and strategies, taking into account the recipient's clinical characteristics, underlying heart failure diagnosis, immunologic risk and comorbidities seem to be the ideal approaches to improve post-transplant morbidity and survival while preventing both rejection and complications of immunosuppression. The aim of the present review is to provide a practical, comprehensive overview of contemporary immunosuppression in heart transplantation. Clinical evidence for immunosuppressive drugs is reviewed and practical approaches are provided. Cardiac allograft rejection classification and up-to-date management are summarized. Expanding therapies, such as photophoresis, are outlined. Drug-to-drug interactions of immunosuppressive agents focused on cardiovascular medications are summarized. Special situations involving heart transplantation such as sarcoidosis, Chagas diseases and pediatric immunosuppression are also reviewed. The evolution of phamacogenomics to individualize immunosuppressive therapy is described. Finally, future perspectives in the field of immunosuppression in heart transplantation are highlighted. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Heart transplantation; clinical management; drug interactions; immunosuppression; pharmacogenomics; rejection

Year:  2020        PMID: 32493185     DOI: 10.2174/1381612826666200603130232

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

Review 1.  Adherence to immunosuppression in adult heart transplant recipients: A systematic review.

Authors:  Tasmeen Hussain; Keira Nassetta; Linda C O'Dwyer; Jane E Wilcox; Sherif M Badawy
Journal:  Transplant Rev (Orlando)       Date:  2021-09-20       Impact factor: 3.943

2.  Incremental value of preoperative right ventricular function in predicting moderate to severe acute kidney injury after heart transplantation.

Authors:  Shuangshuang Zhu; Yanting Zhang; Weihua Qiao; Yixuan Wang; Yuji Xie; Xin Zhang; Chun Wu; Guohua Wang; Yuman Li; Nianguo Dong; Mingxing Xie; Li Zhang
Journal:  Front Cardiovasc Med       Date:  2022-08-09

Review 3.  Cardiovascular effects of immunosuppression agents.

Authors:  Aly Elezaby; Ryan Dexheimer; Karim Sallam
Journal:  Front Cardiovasc Med       Date:  2022-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.